DOI QR코드

DOI QR Code

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

  • Dogan, Erkan (Department of Medical Oncology, Regional Training and Research Hospital) ;
  • Yalcin, Suayib (Department of Medical Oncology, Hacettepe University Institute of Oncology) ;
  • Koca, Dogan (Department of Medical Oncology, Regional Training and Research Hospital) ;
  • Olmez, Aydemir (Department of General Surgery, Van Yuzuncu Yil University)
  • Published : 2012.06.30

Abstract

Background: Hepatocellular carcinoma (HCC), the main malignant tumor of the liver, is very common and highly lethal. The aim of this study was to determine its clinicopathologic characteristics and risk factors in Turkey. Materials and methods: In this study, patients who were diagnosed as suffering from HCC in the period between August 2004 and December 2011 were evaluated retrospectively. Results: A total of 98 patients were included, with a median age 61 (range: 16 to 82). Seventy nine (80.6%) were male 59 (60.2%) were infected with hepatitis B virus (HBV) and 15 (15.3%) with HCV, another 15 (15.3%) being alcohol abusers. Seventy two (73.5%) were at advanced stage and 54 (55.1%) had elevated serum alpha-fetoprotein (AFP). Surgery, chemoembolization, systemic chemotherapy and application of the tyrosine kinase inhibitor sorafenib were the major treatment options. Conclusions: According to our findings HCC is mostly diagnosed in advanced stage and age, being five times more common in males than females. Main risk factors of HCC are HBV infection, HCV infection and alcohol abuse. Elevation in AFP may facilitate early diagnosis of HCC in high risk groups.

Keywords

Hepatocellular carcinoma;etiologic factors;alpha-fetoprotein;early diagnosis;Turkey

References

  1. Alacacioglu A, Somali I, Simsek I, et al (2008). Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol, 38, 683-8. https://doi.org/10.1093/jjco/hyn082
  2. Beasley RP, Hwang LY, Lin CC, et al (1981). Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet, 2, 1129-33.
  3. Bosch FX, Ribes J, Diaz M, Cleries R, (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, 5-16.
  4. Bugianesi E (2007). Non-alcoholic steatohepatitis and cancer. Clin Liver Dis, 11, 191-207. https://doi.org/10.1016/j.cld.2007.02.006
  5. Calvet X, Bruix J, Bru C, et al (1990). Natural history of hepatocellular carcinoma in Spain. Five years' experience in 249 cases. J Hepatol, 10, 311-7. https://doi.org/10.1016/0168-8278(90)90138-H
  6. Chan KM, Chou HS, Wu TJ, et al (2011). Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. A J Surg, 34, 128-34. https://doi.org/10.1016/j.asjsur.2011.08.005
  7. Daniele B, Bencivenga A, Megna AS, et al (2004). Alphafetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology, 127, 108-12. https://doi.org/10.1053/j.gastro.2004.09.023
  8. DeVita VT, Lawrence TS, Rosenberg SA (2008). CANCER Principles & Practice of Oncology. Philadelphia, USA: Lippincott Wiilıams & Wilkins, ?, 1129.
  9. DeVita VT, Lawrence TS, Rosenberg SA (2008). CANCER Principles & Practice of Oncology. Philadelphia, USA: Lippincott Wiilıams & Wilkins, ?, 1130-3.
  10. Degos F, Christidis C, Ganne-Carrie N, et al (2000). Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut, 47, 131-6. https://doi.org/10.1136/gut.47.1.131
  11. Di Bisceglie AM (1997). Hepatitis C and hepatocellular carcinoma. Hepatology, 26, 34-8.
  12. Edge SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th editionof the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4. https://doi.org/10.1245/s10434-010-0985-4
  13. El-Serag HB, Mason AC (1999). Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 340, 745-50. https://doi.org/10.1056/NEJM199903113401001
  14. Fattovich G, Brollo L, Giustina G, et al (1991). Natural history and prognostic factors for chronic hepatitis type B. Gut, 32, 294-8. https://doi.org/10.1136/gut.32.3.294
  15. Fattovich G, Giustina G, Degos F, et al ( 1997). Morbidity and mortality in ompensated cirrhosis type C: a Retrospective follow-up study of 384patients. Gastroenterology, 112, 463-72. https://doi.org/10.1053/gast.1997.v112.pm9024300
  16. Fattovich G, Llovet JM (2006). Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. J Hepatol, 44, 1013-6. https://doi.org/10.1016/j.jhep.2006.04.001
  17. Giannelli G, Antonaci S, (2006). New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis, 38, 854-9. https://doi.org/10.1016/j.dld.2006.05.007
  18. Hajiani E, Masjedizadeh R, Hashemi J, et al (2005). Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J, 26, 974-7.
  19. Hassan MM, Hwang LY, Hatten CJ, et al (2002). Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36, 1206-13. https://doi.org/10.1053/jhep.2002.36780
  20. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  21. Kamangar F, Dores GM, Anderson WF, (2006). Patterns of cancer incidence, mortality,and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50. https://doi.org/10.1200/JCO.2005.05.2308
  22. Koike K, Tsutsumi T, Fujie H, et al (2002) . Molecular mechanism of viral hepatocarcinogenesis. Oncology, 62, 29-37. https://doi.org/10.1159/000048273
  23. Law MG, Roberts SK, Dore GJ, Kaldor JM (2000). Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust, 173, 403-5.
  24. Lee FI (1966). Cirrhosis and hepatoma in alcoholics. Gut, 7, 77-85. https://doi.org/10.1136/gut.7.1.77
  25. Liaw YF, Sung JJ, Chow WC (2004). Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351, 1521-31. https://doi.org/10.1056/NEJMoa033364
  26. Llovet JM, Brú C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38. https://doi.org/10.1055/s-2007-1007122
  27. Lok AS (2004). Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology, 127, 303-9. https://doi.org/10.1053/j.gastro.2004.09.045
  28. Ma C, Chi M, Su H, et al (2012). Evaluation of the Clinical Features of Hepatocellular Carcinoma following Hepatectomy for Different Stages of Hepatocellular Carcinoma. Hepatogastroenterology, 59, ?-?.
  29. Manno M, Camma C, Schepis F, et al (2004). Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology, 127, 756-63. https://doi.org/10.1053/j.gastro.2004.06.021
  30. Marrero JA, Lok AS (2004). Newer markers for hepatocellular carcinoma. Gastroenterology, 127, 113-9. https://doi.org/10.1053/j.gastro.2004.09.024
  31. Moriyama M, Matsumura H, Aoki H, et al (2003). Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. Intervirology, 46, 296-307. https://doi.org/10.1159/000073209
  32. Nagasue N, Ogawa Y, Yukaya H, et al (1985). Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology, 88, 768-72.
  33. Okuda K, Ohtsuki T, ONE AUTHOR, et al (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 56, 918-28. https://doi.org/10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
  34. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43. https://doi.org/10.1016/S1470-2045(01)00486-7
  35. Prates MD, Torres FO (1965). A cancer survey in Lourenço Marques, Portuguese East Africa. J Natl Cancer Inst, 35, 729-57.
  36. Remontet L, Esteve J, Bouvier AM, et al (2003). Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique, 51, 3-30.
  37. Schaefer S (2005). Hepatitis B virus: significance of genotypes. J Viral Hepat, 12, 111-24. https://doi.org/10.1111/j.1365-2893.2005.00584.x
  38. Schoniger-Hekele M, Muller C, Kutilek M, et al (2000). Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol, 12, 941-8. https://doi.org/10.1097/00042737-200012080-00015
  39. Simonetti J, Bulkow L, McMahon BJ, et al (2010). Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology, 51, 1531-7. https://doi.org/10.1002/hep.23464
  40. Taylor-Robinson SD, Foster GR, Arora S, et al (1997). Increase in primary liver cancer in the UK, 1979-94. Lancet, 350, 1142-3.
  41. The CLIP investigators (1998). A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology, 28, 751-5.
  42. Tsujita E, Yamashita Y, Takeishi K, et al (2012). Poor prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma in the modern era. Am Surg, 78, 419-25.
  43. Trevisani F, De NS, Rapaccini G, et al (2002). Semi-annual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol, 97, 734-44. https://doi.org/10.1111/j.1572-0241.2002.05557.x
  44. Tsukuma H, Hiyama T, Tanaka S, et al (1993). Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med, 328, 1797-801. https://doi.org/10.1056/NEJM199306243282501
  45. Ueno Y, Nagata S, Tsutsumi T, et al (1996). Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis, 17, 1317-21. https://doi.org/10.1093/carcin/17.6.1317
  46. Velazquez RF, Rodriguez M, Navascues CA, et al (2003). Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology, 37, 520-7. https://doi.org/10.1053/jhep.2003.50093
  47. Yu SZ (1995). Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol, 10, 674-82. https://doi.org/10.1111/j.1440-1746.1995.tb01370.x
  48. Xu J, Liu C, Zhou L, et al (2012). Distinctions Between clinicopathological factors and prognosis of alphafetoprotein negative and positive hepatocelluar carcinoma patients. Asian Pac J Cancer Prev, 13, 559-62. https://doi.org/10.7314/APJCP.2012.13.2.559

Cited by

  1. Association of Type II Diabetes Mellitus with Hepatocellular Carcinoma Occurrence - a Case Control Study from Kathmandu Valley vol.13, pp.10, 2012, https://doi.org/10.7314/APJCP.2012.13.10.5097
  2. Multicenter Epidemiologic Study on Hepatocellular Carcinoma in Turkey vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2923
  3. Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3915
  4. Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study vol.3, pp.6, 2015, https://doi.org/10.3892/mco.2015.633
  5. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review vol.16, pp.3, 2016, https://doi.org/10.5812/hepatmon.35106